Diaceutics (LON:DXRX) Sets New 12-Month High – Still a Buy?

Shares of Diaceutics PLC (LON:DXRX) reached a new 52-week high on Friday . The company traded as high as GBX 168 and last traded at GBX 163.50, with a volume of 47602 shares trading hands. The stock had previously closed at GBX 161.50.

Analysts Set New Price Targets

DXRX has been the subject of a number of analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 180 price objective on shares of Diaceutics in a research report on Tuesday, July 22nd. Royal Bank Of Canada reduced their price objective on Diaceutics from GBX 195 to GBX 185 and set an “outperform” rating for the company in a research report on Thursday, July 10th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of GBX 175.

Diaceutics Trading Up 1.2%

The firm has a 50 day simple moving average of GBX 154.03 and a 200 day simple moving average of GBX 136.28. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of £138.35 million, a PE ratio of -90.83 and a beta of 0.58.

Diaceutics (LON:DXRX) last issued its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) EPS for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. Equities analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.